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The TREAT-NMD (Translational Research Europe:
Assessment and Treatment of Neuromuscular Diseases)
network was initiated in January 2007. With 21 partners
encompassing clinical and research centres of excellence
in the field together with industrial and advocacy part-
ners, the NoE was launched in response to the need for
infrastructure to support a growing translational agenda
in the field of neuromuscular diseases (NMD), sup-
ported by a strong group of advocacy organisations.
From the outset, TREAT-NMD has embraced the need
to work on a truly international stage by developing
partnerships with groups across the world. This
approach has led to international collaborations on
infrastructure projects such as the definition of animal
models for preclinical studies in NMD, patient registries
and biobanks, a care and trial site registry, harmonised
standards of care, standardised outcome measure assess-
ments and ethical and regulatory interactions. The net-
work has also initiated a new committee to advise on
the multifaceted issues facing drug development in
NMD- the TREAT-NMD advisory committee on thera-
peutics or TACT. From an initial focus on Duchenne
muscular dystrophy and spinal muscular atrophy, the
utility of the tools developed through the network is
now recognised across a wide range of NMD and the
“toolkits” generated are also relevant to other rare dis-
eases with the need to address the pathway to therapy
delivery.
EU investment in the network has provided a model
which has added enormous value to the field. This is
reflected in industrial investment in the tools of the net-
work as well as the ability to generate additional grant
income through the utilisation of the newly available
infrastructure. Guaranteeing the sustainability of such
successful infrastructure projects is an important consid-
eration for the future.
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